Isomorphic Labs, a London-based AI drug discovery company, has raised $2.1 billion in Series B funding led by Thrive Capital. The startup builds the Isomorphic Labs Drug Design Engine (IsoDDE), a unified AI system that predicts biomolecular structures, binding affinities, and novel drug candidates across small molecules, biologics, and antibodies. The capital will scale IsoDDE for biopharma partners, advance an internal pipeline in oncology and immunology toward clinical trials, and fuel hiring across London and U.S. hubs.
Pharma Bets Big on Generative AI
The round follows a $600M investment last year and comes amid surging AI-biotech activity. Insilico Medicine raised $110M Series E in April 2026 to push its AI pipeline, including a Phase II fibrosis drug, while inking a $2.75B commercialization deal with Eli Lilly. Isomorphic's physics-informed models target gaps in generative design for undruggable proteins and cryptic pockets that phenomics or imaging-first rivals overlook.
Structure Prediction Hits Limits
Drug discovery demands precise modeling of protein-ligand interactions, yet traditional physics simulations fail on induced fits and multi-body dynamics. AlphaFold3 advanced structure prediction, but lacks end-to-end design for diverse modalities. Existing tools struggle with novel pocket discovery from sequence alone, leaving vast chemical space unexplored.
IsoDDE Doubles Prediction Accuracy
IsoDDE integrates diffusion models and deep learning to exceed AlphaFold3 by over 2x on protein-ligand benchmarks, outperforming physics baselines in binding affinity. It enables de novo design of antibodies, peptides, and molecular glues by predicting co-folding and dynamic states. As Demis Hassabis, founder and CEO, noted:
"This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug discovery."
The engine powers collaborations with Novartis (now six programs), Eli Lilly, and Johnson & Johnson for multi-target, cross-modality research.
Thrive Capital Doubles Down
Thrive Capital, which led the prior round, signals conviction in Isomorphic's frontier AI, alongside GV, Alphabet, CapitalG, Temasek, MGX, and the UK Sovereign AI Fund. GV's life sciences focus (insitro, Freenome) and Alphabet's DeepMind origins provide strategic validation for scaling to clinic. Ruth Porat, Alphabet CFO, highlighted the progress:
"Isomorphic has already made extraordinary progress in harnessing AI to accelerate drug discovery."
This mix blends growth capital with sovereign backing for global expansion.
AI Drug Market Scales to Billions
The AI drug discovery market stands at $2.35B in 2025, projected to reach $13.77B by 2033 at 24.8% CAGR per Grand View Research. Competitors like Recursion Pharmaceuticals ($452M raised, now public post-Exscientia merger) focus on imaging, while Insilico emphasizes generative small molecules. Isomorphic differentiates with DeepMind-grade accuracy across modalities amid pharma's push for R&D efficiency.
DeepMind Founder Drives Vision
Demis Hassabis spun out Isomorphic from DeepMind, bringing expertise in protein folding via AlphaFold. The leadership includes Chief AI Officer Max Jaderberg and Nobel laureates on the scientific advisory board like Venki Ramakrishnan. This repeat founder team positions the company to bridge AI research and therapeutic reality.
Pipeline Advances to Phase I
Funds target Phase I trials for internal candidates, tripling partnerships beyond Novartis, Lilly, and J&J, and ramping headcount from 371 with roles in ML, clinical operations, and regulatory affairs. U.S. expansion via Cambridge and San Francisco hubs accelerates deployments.